HOME > ARCHIVE
ARCHIVE
- Japanese Healthcare Q&A (2)
October 20, 2003
- AstraZeneca Reorganizes Primary Care Business Unit
October 20, 2003
- Korosho WG Hears 7 Bodies on Deregulation of OTC Drug Sales
October 20, 2003
- WEBSITE NEWS
October 20, 2003
- Korosho WG Discusses New "Health Food" System
October 20, 2003
- Nippon Chemiphar to Launch 1st Generic Codeveloped with Ranbaxy in 2005
October 20, 2003
- MEDICAL DEVICE NEWS IN BRIEF
October 20, 2003
- Mochida Returns Toyama Plant to Meiji Yakuhin
October 20, 2003
- Incoming Banyu President Hirate Expresses His Hopes
October 20, 2003
- BUSINESS NEWS IN BRIEF
October 13, 2003
- Bacterial Screening Also Essential for Platelet Products: bioMerieux
October 13, 2003
- GSK's Epivir Gets Add. Formulation: CDFS Panel
October 13, 2003
- DIAGNOSTIC NEWS IN BRIEF
October 13, 2003
- Kirin's Busulfan Designated as Orphan
October 13, 2003
- Olympus: EndoArm for Neurosurgery
October 13, 2003
- Chuikyo Summarizes Discussions on Revision of Medical Fees
October 13, 2003
- Korosho WG to Screen OTC Drugs for Sales Deregulation
October 13, 2003
- Insurance Coverage Expected Soon for M-VAC Therapy
October 13, 2003
- 10 Suspected Deaths Due to OTC Drugs Since FY2001: Korosho
October 13, 2003
- Korosho Approves Azwell-Fukujin's Business Rebuilding Plan
October 13, 2003
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
